Goldman Sachs Group Inc Pacira Bio Sciences, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 343,383 shares of PCRX stock, worth $6.69 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
343,383
Previous 352,870
2.69%
Holding current value
$6.69 Million
Previous $10.1 Million
48.78%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding PCRX
# of Institutions
263Shares Held
50.4MCall Options Held
429KPut Options Held
391K-
Black Rock Inc. New York, NY8.01MShares$156 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.3MShares$103 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA4.96MShares$96.6 Million0.18% of portfolio
-
State Street Corp Boston, MA2.01MShares$39.2 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.98MShares$38.5 Million0.05% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $892M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...